Last updated on September 2018

Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes


Brief description of study

This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Management of a tobacco treatment intervention compares varenicline (a drug that reduces the craving and withdrawal symptoms that occur with abstinence from nicotine) and behavioral interventions (consisting of a brief clinician-delivered intervention and tobacco quitline [tobacco cessation service available through a toll-free telephone number] follow-up) with placebo (a pill with no active medication) along with similar behavioral interventions. It is not yet known whether management of a tobacco treatment intervention is more effective in reducing surgical complications than placebo.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To determine if varenicline plus a behavioral intervention consisting of a brief clinician-delivered intervention and tobacco quitline follow-up, decreases postsurgical complications through 24 weeks after surgery when compared to placebo plus the behavioral intervention in lung cancer patients who undergo surgery and are motivated to stop smoking.

SECONDARY OBJECTIVES:

I. To compare changes from baseline to 12 and 24 weeks after surgery in the patient quality of life (Linear Analogue Self-Assessment [LASA]-12) domains between the intervention (varenicline) and control group (placebo).

II. To compare changes from baseline to 6, 12 and 24 weeks after surgery in the patient quality of life related domains (LASA) for the Patient Health Questionnaire (PHQ)-9 and Smoking Self Efficacy Questionnaire (SEQ)12 between the intervention and control groups.

III. To compare the proportion of patients 12 weeks and 24 weeks after surgery who endorse ("Was It Worth It") each treatment (intervention versus [vs] control groups).

IV. To compare post-operative care (as measured by length of hospital and high dependency unit stay) between the intervention and control groups.

V. To compare treatment adherence between the intervention and control groups. VI. To compare rates of smoking abstinence between the intervention and control groups as a covariate of the primary outcome only.

Clinical Study Identifier: NCT02856581

Contact Investigators or Research Sites near you

Start Over

Christopher M. Reynolds

Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, MI United States
1.2miles
  Connect »

Christopher M. Reynolds

Lymphoma Clinic of Michigan
Grosse Pointe Woods, MI United States
1.63miles
  Connect »

Christopher M. Reynolds

Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, MI United States
1.63miles
  Connect »

Christopher M. Reynolds

Saint John Hospital and Medical Center
Detroit, MI United States
2.09miles
  Connect »

Christopher M. Reynolds

Macomb Hematology Oncology PC
Warren, MI United States
6.36miles
  Connect »

Christopher M. Reynolds

Michigan Breast Specialists-Warren
Warren, MI United States
6.36miles
  Connect »

Christopher M. Reynolds

Saint John Macomb-Oakland Hospital
Warren, MI United States
6.36miles
  Connect »

Christopher M. Reynolds

Advanced Breast Care Center PLLC
Warren, MI United States
6.45miles
  Connect »

Christopher M. Reynolds

Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren, MI United States
6.95miles
  Connect »

Christopher M. Reynolds

Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights, MI United States
9.44miles
  Connect »